Ontology highlight
ABSTRACT:
PROVIDER: PRJNA951203 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR24039110_1.fastq.gz | Fastqsanger.gz | |||
| SRR24039110_2.fastq.gz | Fastqsanger.gz | |||
| SRR24039111_1.fastq.gz | Fastqsanger.gz | |||
| SRR24039111_2.fastq.gz | Fastqsanger.gz | |||
| SRR24039112_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 33 |
Similar Datasets
Project description:The novel Traditional Chinese Medicine Ramulus Mori (Sangzhi) alkaloid tablets (SZ-A) are approved by The China National Medical Products Administration for the treatment of type 2 diabetes mellitus (T2DM). However, the extensive pharmacological characteristics and the underlying mechanism are unknown. This study investigated the mechanisms by which SZ-A ameliorates glucose metabolism in KKAy mice, an animal model of T2DM. Diabetic KKAy mice were treated intragastrically with SZ-A once daily for 8 weeks, after which glucose levels, lipid metabolism, gut microbiome, systemic inflammatory factors, luminal concentrations of short-chain fatty acids (fecal samples), and ileal proteomic changes were evaluated. The ileum tissues were collected, and the effects of SZ-A on pathological inflammatory damage were evaluated by hematoxylin and eosin staining, immunofluorescence, and immunohistochemistry. The mRNA and protein expression levels of various inflammatory markers, including monocyte chemoattractant protein-1 and phosphorylated nuclear factor kappa B p65, were detected in the ileum tissues. SZ-A improved glucose metabolism with enhanced insulin response and elevated glucagon-like peptide 1 (GLP-1) during the glucose tolerance test in diabetic KKAy mice. Gut microbiota analysis demonstrated that SZ-A administration elevated the abundance of Bacteroidaceae and Verrucomicrobia, reduced the levels of Rikenellaceae and Desulfovibrionaceae; and increased the concentrations of fecal acetic and propionic acids compared to the diabetic model group. Additionally, SZ-A markedly improved ileal inflammatory injury and pro-inflammatory macrophage infiltration and improved intestinal mucosal barrier function in diabetic KKAy mice. SZ-A also attenuated the levels of circulating endotoxin, pro-inflammatory cytokines, and chemokines in the mice sera. Collectively, SZ-A ameliorated the overall metabolic profile including glucose and lipid metabolism in KKAy mice, which may be associated with an improvement in GLP-1 and insulin secretion, at least in part by modulating the gut microbiome and relieving the degree of ileal and systemic inflammation.
2021-09-10 | PXD024241 | Pride
Project description:Auricularia auricula is a well-known traditional edible and medicinal fungus with high nutritional and pharmacological values, as well as metabolic and immunoregulatory properties. However, the exact mechanisms underlying the effects of Auricularia auricula polysaccharides (AAP) on obesity and related metabolic endpoints, including the role of the gut microbiota, remain insufficiently understood. To determine the mechanistic role of the gut microbiota in observed anti-obesogenic effects AAP, faecal microbiota transplantation (FMT) and pseudo germ-free mice model treated with antibiotics were also applied, together with 16S rRNA genomic-derived taxonomic profiling. HFD murine exposure to AAP thwarted weight-gains, reduced fat depositing, together with upregulating thermogenesis proteomic biomarkers within adipose tissue. These effects were associated with diminished intestine/bloodstream-borne lipid transportation, together with enhanced glucose tolerance. FMT administered in tandem with antibiotic treatment demonstrated the intestinal microbiota was necessary in deploying AAP anti-obesogenic functions. Intestine-dwelling microbial population assessments discovered AAP to enhance (in a selective manner) Papillibacter cinnamivorans, a commensal bacterium having reduced presence within HFD mice. Notably, HFD mice treated with oral formulations of Papillibacter cinnamivorans diminished obesity and was linked to decreased intestinal lipid transportation. Datasets from the present study show that AAP thwarted dietary-driven obesity and metabolism-based disorders through regulating intestinal lipid transportation, a mechanism that is dependent on the gut commensal Papillibacter cinnamivorans. These results indicated AAP and Papillibacter cinnamivorans as newly identified pre- and probiotics that could possibly serve as novel countermeasure against obesity.
2022-05-03 | GSE201951 | GEO
Project description:Auricularia auricula is a well-known traditional edible and medicinal fungus with high nutritional and pharmacological values, as well as metabolic and immunoregulatory properties. However, the exact mechanisms underlying the effects of Auricularia auricula polysaccharides (AAP) on obesity and related metabolic endpoints, including the role of the gut microbiota, remain insufficiently understood. To determine the mechanistic role of the gut microbiota in observed anti-obesogenic effects AAP, faecal microbiota transplantation (FMT) and pseudo germ-free mice model treated with antibiotics were also applied, together with 16S rRNA genomic-derived taxonomic profiling. HFD murine exposure to AAP thwarted weight-gains, reduced fat depositing, together with upregulating thermogenesis proteomic biomarkers within adipose tissue. These effects were associated with diminished intestine/bloodstream-borne lipid transportation, together with enhanced glucose tolerance. FMT administered in tandem with antibiotic treatment demonstrated the intestinal microbiota was necessary in deploying AAP anti-obesogenic functions. Intestine-dwelling microbial population assessments discovered AAP to enhance (in a selective manner) Papillibacter cinnamivorans, a commensal bacterium having reduced presence within HFD mice. Notably, HFD mice treated with oral formulations of Papillibacter cinnamivorans diminished obesity and was linked to decreased intestinal lipid transportation. Datasets from the present study show that AAP thwarted dietary-driven obesity and metabolism-based disorders through regulating intestinal lipid transportation, a mechanism that is dependent on the gut commensal Papillibacter cinnamivorans. These results indicated AAP and Papillibacter cinnamivorans as newly identified pre- and probiotics that could possibly serve as novel countermeasure against obesity.
2022-05-03 | GSE201950 | GEO
Project description:Voglibose is an α-glycosidase inhibitor with anti-inflammatory effects on the intestine, but the underlying mechanism is not clear. Our study defined the dynamic changes of the differentially expressed genes after treatment of voglibose in diabetic KKAy mice, and provide basis for comprehensive understanding of the disease at molecular level. We investigated gene expression alteration after a long-term treatment of voglibose in diabetic KKAy mice.
2022-10-15 | GSE215823 | GEO
Project description:Background & Aims: Non-alcoholic fatty liver disease (NALFLD)-associated changes in gut microbiota are important drivers of disease progression toward fibrosis. Therefore, reversing microbiota alterations could ameliorate NAFLD progression. Oat beta-glucan, a non-digestible polysaccharides, has shown promising therapeutic effects on hyperlipidemia associated with NAFLD, but its impact on gut microbiota and most importantly NAFLD fibrosis remains unknown. Methods: We performed detailed metabolic phenotyping including body composition, glucose tolerance, and lipid metabolism as well as comprehensive characterization of the gut-liver axis in a western-style diet (WSD)-induced model of NAFLD and assessed the effect of a beta-glucan intervention on early and advanced liver disease. Gut microbiota was modulated using broad-spectrum antibiotic (Abx) treatment. Results: Oat beta-glucan supplementation did not affect WSD-induced body weight gain, glucose intolerance, and the metabolic phenotype remained largely unaffected. Interestingly, oat beta-glucan dampened NAFLD inflammation, associated with significantly reduced monocyte-derived macrophages (MoMFs) infiltration, fibroinflammatory gene expression, and strongly reduced fibrosis development. Mechanistically, this protective effect was not mediated by changes in bile acid composition or signaling, but was dependent on gut microbiota and was lost upon Abx treatment. Specifically, oat beta-glucan partially reversed unfavorable changes in gut microbiota, resulting in an expansion of protective taxa, including Ruminococcus, and Lactobacillus followed by reduced translocation of TLR ligands. Conclusions: Our findings identify oat beta-glucan as a highly efficacious food supplement that dampens inflammation and fibrosis development in diet-induced NAFLD. These results, along with its favorable dietary profile, suggest that it may be a cost-effective and well-tolerated approach to preventing NAFLD progression and should be assessed in clinical studies.
2024-01-01 | GSE246738 | GEO
Project description:Background: Acute pancreatitis (AP) is a common severe digestive disorder, with severity linked to high-fat diets (HFD). HFD may exacerbate AP by promoting inflammation and altering gut microbiota. Astragalus polysaccharides (APS) possess anti-inflammatory properties, but it is unclear if APS supplementation can mitigate HFD's detrimental effects on AP by modulating gut microbiota. This study investigates the mechanisms by which APS improves HFD-induced AP exacerbation. In this study, C57BL/6 mice were fed HFD or a standard diet, with or without APS, for 12 weeks. AP was induced via intraperitoneal caerulein injection. Analyses included ELISA, Western blotting, histology, immunohistochemistry, immunofluorescence, single-cell RNA sequencing (scRNA-seq), 16S rRNA sequencing of gut microbiota, and short-chain fatty acid (SCFA) analysis to evaluate inflammation and cellular changes. Results: HFD significantly increased AP severity, indicated by elevated serum enzyme and pro-inflammatory cytokine levels, along with extensive pancreatic damage. Single-cell RNA sequencing (scRNA-seq) showed a notable rise in ICAM1+ neutrophils and activation of the NF-κB/necroptosis pathway in HAP mice. APS alleviated these effects by decreasing ICAM1+ neutrophil infiltration, downregulating the NF-κB pathway, and reducing necroptosis. Moreover, APS restored gut microbiota balance, significantly boosting Lactobacillus reuteri (L. reuteri) abundance and propionate (PA) levels. Treatments with L. reuteri and PA independently mitigated HFD-induced AP severity, indicating that APS's protective effects are microbiota-dependent. Conclusion: APS improves HFD-induced gut dysbiosis and intestinal barrier dysfunction by enriching L. reuteri and PA, effectively reducing AP exacerbation. Our findings highlight the gut-pancreas axis as a promising target for addressing AP severity.
2024-10-22 | GSE279876 | GEO
Project description:Introduction: Chronic sleep fragmentation (SF) is prevalent in contemporary human society, highlighting detrimental effects on glucose metabolism and adipose tissue morphology, which is closely linked to gut microbiota composition. However, it remains unclear whether sleep recovery (SR) after prolonged SF can ameliorate glucose metabolism, influence the transcriptome of inguinal white adipose tissue (iWAT), and whether these effects align with alterations in the gut microbiota. Methods: Mice were subjected to 8 weeks of SF and subsequently allowed 2 weeks of SR. We assessed glucose tolerance through intraperitoneal glucose tolerance tests (ipGTT), analyzed gut microbiota via 16s rDNA amplicon sequencing, and examined transcriptomic alterations in iWAT using RNA sequencing. Results: Despite the two-week SR following chronic SF, significant glucose intolerance persisted, accompanied by subtle shifts in the gut microbiota and alterations in gene expression within iWAT. The top hub genes Ncapg, Cenpe, and Tik were identified from the protein-protein interaction network. Conclusion: Even followed by a brief period of SR, prolonged SF still led to ongoing glucose intolerance and alterations in the adipose tissue transcriptome in mice. These changes were intertwined with modifications in the gut microbiome. The shifts in gut microbiota may play a pivotal role in understanding the sustained negative effects of SF.
2024-06-30 | GSE248189 | GEO